Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450

Biotechnology and Bioengineering

Volumn 93, Issue 3, 2006, Pages 494-499

  Otey, Christopher R ^a   Bandara, Geethani ^b   Lalonde, James ^b,c   Takahashi, Katsuyuki ^b,d   Arnold, Frances H ^a,b  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b California Institute of Technology   (United States)

^c R and D Project Development and Management   (United States)

^d MITSUI CHEMICALS INC   (Japan)

Author keywords

Bioconversion; Cytochrome P450 BM3; Directed evolution; Drug metabolism; Drug metabolites; Peroxide shunt

Indexed keywords

BACTERIA; BIOCONVERSION; CATALYSIS; DRUG PRODUCTS; HYDROGEN PEROXIDE;

DRUG METABOLITES; PEROXIDE SHUNT;

METABOLITES;

BACTERIAL ENZYME; CYTOCHROME P450; DRUG METABOLITE; ENZYME VARIANT; HYDROGEN PEROXIDE; OXIDOREDUCTASE; OXYGEN; OXYGENASE; PEROXIDE; PROPRANOLOL DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; BACILLUS MEGATERIUM; BIOCATALYST; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SYNTHESIS; LABORATORY; NONHUMAN; PROTEIN DOMAIN;

BACILLUS MEGATERIUM; BACTERIAL PROTEINS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DIRECTED MOLECULAR EVOLUTION; GENES, BACTERIAL; HEME; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; PROPRANOLOL; PROTEIN ENGINEERING;

BACILLUS MEGATERIUM; BACTERIA (MICROORGANISMS);

EID: 32544436092     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20744     Document Type: Article

References (38)

1. Barnes HJ, Arlotto MP, Waterman MR. 1991. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci USA 88(13):5597-5601.
2. Carmichael AB, Wong LL. 2001. Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem 268(10):3117-3125.
3. Cirino PC, Arnold FH. 2002. Regioselectivity and activity of cytochrome P450 BM-3 and mutant F87A in reactions driven by hydrogen peroxide. Adv Synth Catal 344(9):932-937.
4. Cirino PC, Arnold FH. 2003. A self-sufficient peroxide-driven hydroxylation biocatalyst. Angew Chem Int Ed Engl 42(28):3299-3301.
5. Coltart DJ, Shand DG. 1970. Plasma propranolol levels in the quantitative assessment of beta-adrenergic blockade in man. Br Med J 3(725):731-734.
6. Fitzgerald JD, O'Donnell SR. 1971. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol 43(1):222-235.
7. Graham-Lorence S, Truan G, Peterson JA, Falck JR, Wei S, Helvig C, Capdevila JH. 1997. An active site substitution, F87V, converts cytochrome P450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase. J Biol Chem 272(2):1127-1135.
8. Guengerich FP. 2001. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14(6): 611-650.
9. Guengerich FP. 2003. Cytochromes P450, drugs, and diseases. Mol Interv 3(4):194-204.
10. Guengerich FP, Gillam EM, Shimada T. 1996. New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 26(5):551-583.
11. Haines DC, Tomchick DR, Machius M, Peterson JA. 2001. Pivotal role of water in the mechanism of P450BM-3. Biochemistry 40(45):13456-13465.
12. Johnson MD, Zuo H, Lee K, Trebley JP, Rae JM, Weatherman RV, Zeruesanay D, Flockhart DA, Skaar TC. 2004. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel metabolite of tamoxifen. Breast Cancer Res Treat 207:1-9.
13. Kubo T, Peters MW, Meinhold P, Arnold FH. 2005. Enantioselective epoxidation of terminal alkenes to (R)- and (S)-epoxides by engineered cytochromes P450 BM-3. Chemistry Eur J (in press).
14. Lewis DFV. 2001. Guide to Cytochromes P450: structure and function. London, New York: Taylor & Francis.
15. Lewis DF. 2004. 57 varieties: The human cytochromes P450. Pharmacogenomics 5(3):305-318.
16. Li H, Poulos TL. 1997. The structure of the cytochrome p450BM-3 haem domain complexed with the fatty acid substrate, palmitoleic acid. Nat Struct Biol 4(2):140-146.
17. Li QS, Ogawa J, Schmid RD, Shimizu S. 2001a. Engineering cytochrome P450 BM-3 for oxidation of polycyclic aromatic hydrocarbons. Appl Environ Microbiol 67(12):5735-5739.
18. Li QS, Ogawa J, Schmid RD, Shimizu S. 2001b. Residue size at position 87 of cytochrome P450 BM-3 determines its stereoselectivity in propylbenzene and 3-chlorostyrene oxidation. FEBS Lett 508(2):249-252.
19. 2 inactivation of cytochrome P450BM-3. Biochem Biophys Res Commun 280(5):1258-1261.
20. Markham A, Wagstaff AJ. 1998. Fexofenadine. Drugs 55(2):269-274.
21. Masubuchi Y, Hosokawa S, Horie T, Suzuki T, Ohmori S, Kitada M, Narimatsu S. 1994. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 22(6):909-915.
22. Meinhold P, Peters MW, Chen MMY, Takahashi K, Arnold FH. 2005a. Direct conversion of ethane to ethanol by engineered cytochrome P450 BM3. Chembiochem (in press: published online: DOI 10.1002/ cbic.200500261).
23. Meinhold P, Peters MW, Hartwick A, Hernandez AR, Arnold FH. 2005b. Engineered cytochrome P450 BM-3 variants with terminal hydroxylation activity. Chembiochem (in press).
24. Munzer DF, Meinhold P, Peters MW, Feichtenhofer S, Griengl H, Arnold FH, Glieder A, de Raadt A. 2005. Stereoselective hydroxylation of an achiral cyclopentanecarboxylic acid derivative using engineered P450s BM-3. Chem Commun 20:2597-2599.
25. Nakagawa S, Ishino S, Teshiba S. 1996. Construction of catalase deficient Escherichia coli strains for the production of uricase. Biosci Biotechnol Biochem 60(3):415-420.
26. Noble MA, Miles CS, Chapman SK, Lysek DA, MacKay AC, Reid GA, Hanzlik RP, Munro AW. 1999. Roles of key active-site residues in flavocytochrome P450 BM3. Biochem J 339(Pt 2):371-379.
27. Oatis JE Jr., Russell MP, Knapp DR, Walle T. 1981. Ring-hydroxylated propranolol: Synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. J Med Chem 24(3):309-314.
28. Otey CR, Joern JM. 2003. High-throughput screen for aromatic hydroxylation. In: Arnold FH, Georgiou G, editors. Directed enzyme evolution: Screening and selection methods. Totowa, NJ: Humana Press, pp 141-148.
29. Parikh A, Gillam EM, Guengerich FP. 1997. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15(8):784-788.
30. Peters MW, Meinhold P, Glieder A, Arnold FH. 2003. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3. J Am Chem Soc 125(44):13442-13450.
31. Rushmore TH, Reider PJ, Slaughter D, Assang C, Shou M. 2000. Bioreactor systems in drug metabolism: Synthesis of cytochrome P450-generated metabolites. Metab Eng 2(2):115-125.
32. Schenkman JB, Jansson I. 1998. Spectral analyses of cytochromes P450. In: Phillips IR, Shephard EA, editors. Cytochrome P450 protocols. Totowa, New Jersey: Human Press, Inc. pp 25-33.
33. Schwaneberg U, Schmidt-Dannert C, Schmitt J, Schmid RD. 1999. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Anal Biochem 269(2): 359-366.
34. Shand DG. 1975. Drug therapy: Propranolol. N Engl J Med 293(6):280-285.
35. Sono M, Roach MP, Coulter ED, Dawson JH. 1996. Heme-containing oxygenases. Chem Rev 96(7):2841-2888.
36. Suzuki M, Christians FC, Kim B, Skandalis A, Black ME, Loeb LA. 1996. Tolerance of different proteins for amino acid diversity. Mol Divers 2 (1-2):111-118.
37. Upthagrove AL, Nelson WL. 2001. Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol derivatives. Preparation, identification of metabolite regioisomers, and metabolism by CYP2D6. Drug Metab Dispos 29(11):1377-1388.
38. Vail RB, Homann MJ, Hanna I, Zaks A. 2005. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J Ind Microbiol Biotechnol 32(2):67-74.